Business Wire

Women’s Brain Project and Altoida Announce Results Highlighting Sex-Based Differences Using Predictive Digital Biomarker in Alzheimer’s Disease

Share

The Women’s Brain Project, an international non-profit organization studying gender and sex determinants to brain and mental health and Altoida, a precision neurology company pioneering non-invasive brain health diagnostics using AI and augmented reality (AR), today announced results from a study showing sex-based differences using digital biomarker data collected from Altoida’s digital cognitive assessment platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615005079/en/

Published inEPMA Journal, the study explored sex differences in Altoida’s digital cognitive assessment platform in a sample of 568 subjects consisting of a clinical dataset (mild cognitive impairment and dementia due to Alzheimer’s Disease) and a healthy population. The study results found that a biological sex classifier built on digital biomarker features, captured using Altoida’s application, achieved a 75% performance rate in predicting biological sex in healthy individuals, indicating significant differences in neurocognitive performance signatures between males and females.

The discernible differences seem to decline in subjects with mild cognitive impairment (MCI) or overt Alzheimer’s Disease (AD), independent of age. In the healthy population, the primary differentiating features are micro hand gestures detectable on a wearable, that measured accelerometric data. In this assessment domain, the accuracy reached 80 percent versus the overall neurocognitive Altoida performance. The study found that sex differences can be observed via digital biomarkers, which has the potential to impact diagnosis and treatment of AD.

“Our research shows how digital biomarkers can detect sex-based differences which are often overlooked when using standardized cognitive neuropsychological assessment,” said Antonella Santuccione Chadha, M.D., CEO and Co-Founder Women's Brain Project and Chief Medical Officer at Altoida. “These findings support the need for researchers and drug developers to account for sex-based characteristics in investigating prospective treatments for Alzheimer’s Disease.”

“Our ultimate goal is to build an integrated framework for sex-based cognitive assessment to predict, monitor and provide precision treatment of neurodegenerative disease,” said Travis Bond, CEO, Altoida. “Such a framework could be used for early detection of the disease, and enables both targeted prevention strategies and personalized Alzheimer’s treatment for patients. By integrating sex with risk stratification based on genetics and individual risk factors with the use of digital biomarker monitoring applications, this will enable the early detection and treatment of symptoms, when a patient has MCI, before development into Alzheimer’s.”

Study results highlight sex-based differences

An MCI diagnosis is determined often later in females, compared to males. This study suggests that using sex-adjusted tools for diagnosis (or sex-adjusted cut-offs) may be needed to improve diagnostic precision. Predictive diagnostics using AD biomarkers in the pre-symptomatic or oligosymptomatic (MCI) stage, followed by targeted preventions and treatment personalized to those individuals considered high risk, are increasingly considered to represent the best chance at successful AD management.

The performance dropped when this classifier was applied to more advanced stages on the AD continuum, including MCI and dementia, suggesting that sex differences might be disease-stage dependent. The results indicate that neurocognitive performance signatures built on data from digital biomarker features are different between men and women. These results stress the need to integrate traditional approaches to dementia research with digital biomarker technologies and personalized medicine perspectives to achieve more precise predictive diagnostics, targeted prevention, and customized treatment of cognitive decline.

The results may also enable researchers to better understand the pathophysiological mechanisms of the disease, which might differ between sexes, with opportunities for personalized treatment. From a predictive medicine perspective, including sex differences might make predictions more precise, especially with algorithms that incorporate multiple variables. In particular, considering sex differences may improve the ability to predict fast decliners in MCI patients, which is a key element for planning therapy and care options. From a precision medicine perspective, whether a patient is a male or female makes a difference, based on the study data. More data on sex differences could guide future clinical practice, informing choices for ad-hoc prevention, diagnosis and treatment options.

These findings should be integrated with the most powerful recent developments in digital medicine to build models of disease development that can fully integrate the effect of sex, digital biomarker technology being one of the most promising tools when developing drugs or digital therapeutics in AD. The study was conducted to show the research community that there are potential sex differences in cognitive testing in Alzheimer’s, in order to implement measures to mitigate potential biases in clinical application.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Women’s Brain Project
Nelli Sanne
nelli.sanne@kontx.ch

Altoida
Kimberly Ha
KKH Advisors
kimberly.ha@kkhadvisors.com
917-291-5744

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY ® (fremanezumab)24.6.2022 18:54:00 CEST | Press release

Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit

Brigade-M3 European Acquisition Corp. 2021 Annual Report24.6.2022 16:59:00 CEST | Press release

Brigade-M3 European Acquisition Corp. (the “Company”), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, today published its annual report for the period 21 April 2021 to 31 December 2021. The full report can be downloaded from the Company’s website via the following link: https://www.brigadem3eac.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does n

PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop24.6.2022 16:41:00 CEST | Press release

PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220624005314/en/ PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. (Photo: Business Wire) News of the partnership was shared at an event hosted by 10KTF last night in New York. Their event was one of many hosted during the week of NFT.NYC, a conference attended by crypto industry professionals, traders, and other web3 enthusiasts. The official announcement confirms weeks of speculation after PUMA tw

Suzano outlines ESG milestone achievements and commitments at second annual ESG call24.6.2022 16:14:00 CEST | Press release

Suzano, the world’s largest hardwood pulp producer, today held its second annual ESG Call centered around its ambition to be a ‘regenerative company for a regenerative society’. Today’s ESG Call spotlighted measurable progress and ambitions across three core areas of action: climate change, biodiversity and social development. On Climate Change, the ACT initiative of the French Government and CDP scored Suzano ahead of its pulp and paper industry peers in virtually every metric. In 2021, Suzano brought forward its target for removing 40 million tons of carbon dioxide from the atmosphere from 2030 to 2025 which is being achieved through improvements to its industrial processes, such as systematically replacing the use of fossil fuels at its industrial plants with biomass, and through conversion of degraded land. As part of the company’s social commitments, Suzano launched a target in 2020 to lift 200,000 people out of poverty. This is more than pertinent, given that in Brazil, 10% of th

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)24.6.2022 15:38:00 CEST | Press release

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that CRYSVITA® (burosumab) be approved for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with less than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with p